Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 30;15:1449–1478. doi: 10.2147/OTT.S384293

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Tecik and Adan.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

FLT3-ITD signal transduction.¹^,⁹

Notes: Data from the references: ©2012 Grafone et al, Licensee PAGE Press, Italy. Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev. 2012;6(1):e8-e8 under Creative Commons CC BY-NC 3.0.¹ ©2017 Hospital et al, Licensee Dove Medical Press Limited. Hospital MA, Green AS, Maciel TT, et al, FLT3 inhibitors: clinical potential in acute myeloid leukemia. Onco Targets Ther. 2017;10:607-615 under Creative Commons CC BY-NC 3.0.⁹